Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 137-140 , March 2008

Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy

Received 1 September 2006 ,Revised 16 April 2007 ,Accepted 16 April 2007.

References 

  1. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964–969
  2. Lamm DL. Management of bladder cancer. J Urol. 2004;171:2482–2483
  3. DeVeale B, Brummel T, Seroude L. Immunity and aging: The enemy within?. Aging Cell. 2004;3:195–208
  4. Malkowicz SB. Management of superficial bladder cancer. In:  Walsh PC,  Retik AB,  Vaughan ED, et al. editor. Campbell’s Urology. 8th ed.. Philadelphia (PA): W.B. Saunders Co; 2002;p. 2789–2792
  5. Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000;37(Suppl):33–36
  6. Huang TC. Management of complications of bacillus Calmette-Guerin immunotherapy in the treatment of bladder cancer. Ann Pharmacother. 2000;34:529–532
  7. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol. 1990;144:1328–1330
  8. Gonzalez JA, Marcol BR, Wolf MC. Complications of intravesical bacillus Calmette-Guerin: A case report. J Urol. 1992;148:1892–1893
  9. Marans HY, Bekirov HM. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma. J Urol. 1987;137:111–112
  10. Leebeek FW, Ouwendijk RJ, Kolk AH, et al. Granulomatous hepatitis caused by bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut. 1996;38:616–618
  11. Orikasa K, Namima T, Ota S, et al. Acute eosinophilic pneumonia associated with intravesical bacillus Calmette-Guerin therapy of carcinoma in situ of the bladder. Int J Urol. 2003;10:622–624
  12. Kanematsu A, Inoue T, Iwamura H, et al. Intravesical bacillus Calmette-Guerin instillation for patients over 80 years old. Hinyokika Kiyo. 1998;44:253–257
  13. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987;137:220–224
  14. Griffiths TRL, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol. 2002;167:2408–2412
  15. P’ng KB, Walsh MD, Seymour GJ, et al. The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guerin efficacy for superficial bladder cancer. Aust N Z J Surg. 1993;63:127–130
  16. Hudson MA, Brown EJ, Ritchey JK, et al. Modulation of fibronectin-mediated Bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 1991;51:3726–3732
  17. Hudson MA, Yuan JJ, Catalona WJ, et al. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol. 1990;144:1362–1364
  18. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970

☆ This study was funded in part by a grant from the Georgia Cancer Coalition.

PII: S1078-1439(07)00126-3

doi: 10.1016/j.urolonc.2007.04.005

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 137-140 , March 2008

Article Tools

* Image Usage & Resolution